Opinion|Videos|June 26, 2024
Deucravacitinib Safety Data and Treatment Selection Considerations
Bruce Strober, MD, PhD, and Linda Stein Gold, MD, provide clinical insights on long-term safety data for deucravacitinib and selecting the right treatment for the right patient.
Advertisement
0:05 Long-term Safety Data of Deucravacitinib
6:55 Selecting the Right Treatment for the Right Patient
Advertisement
Related to this article
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
6 Nephrology Headlines You Missed in September 2026
5